Below you can find more information about PepVax for investors
PepVax, Inc. is an early stage life sciences technology development company with a foremost goal to develop therapeutics for cancer through the rapid and efficient development of cutting edge immunotherapy candidates using bioinformatics and outsourced laboratory resources.
PepVax, Inc. is a private, early-stage biotechnology company developing novel immunotherapy biologics to treat various cancers. PepVax’s scientific co-founder, Dr. Anton Dormer, is a leading expert in peptide design and protein development through computational biology, having developed bioinformatics tools for vaccine design of various infectious diseases. Business co-founder, Mr. Mahesh Narayanan, is an experienced entrepreneur in the field of biotechnology, leading the business development strategies for PepVax.
Immunotherapy, which encompasses vaccines, oncolytic viruses, adjuvants, and adoptive t-cell technologies, could create a market of $40 billion by 2025, changing the entire landscape of oncology. PepVax will be addressing three problems that currently exist with immunotherapy: make the existing therapies more effective; decrease the time it takes to make cancer therapeutics; and reduce the cost of immunotherapy. Hence, PepVax is designed to enhance this market with its small core of key employees, strong outsourced partners, and a large library of marketable products.
PepVax has a method that allows for the rapid development of key cancer immunotherapy candidates that could be licensed to the biotechnology and pharmaceutical industry, giving them opportunity to develop in vitro proven treatments, establishing credibility of our rapid development model. Likewise, PepVax has created a novel plasmid delivery system that is designed to enhance the effectiveness of both prophylactic and therapeutic vaccines for both human and veterinary applications.
PepVax is seeking equity financing to complete development of its lead pre-IND programs, enter Phase I clinical trials with its first therapeutic candidates.
PepVax is currently seeking equity financing, sufficient to enable the company to:
• Develop, characterize, and scale production of a PVX-009, a DNA- based vector expression system for MAGE A;
• Complete pre-IND work for PVX-009;
• Ramp business development efforts aimed at securing strategic partnerships, alliances, and licensees.
The Investment will allow us to complete the preclinical studies and submit an Investigation New Drug (IND) application to the U.S FDA in the next 18 months. PepVax’s technology has the potential to change the entire cancer treatment landscape and we strongly believe we can provide hope to patients that currently have none.
June, 2015: Paper published by PepVax describing the Epitope specificity and protein signaling interactions driving epidemic occurrences of Ebola disease. Ebolavirus has as main hosts, humans and nonhuman primates where its pathogenic effects result to serious hemorrhagic fever with lethal...
August, 2014: Paper published by PepVax describing a novel strategy of In silico peptide vaccine design for Streptococcus mutans. Several attempts have been made towards the development of a viable vaccine for Streptococcus mutans (S. Mutans). This Gram positive bacterium is..."
TEDCO Press Release: Maryland Entrepreneur List Success Story
Washington Business Journal: Can Indiegogo fund biotech? PepVax bets on it